---
title: "Mirum Pharmaceuticals, Inc. (MIRM.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MIRM.US.md"
symbol: "MIRM.US"
name: "Mirum Pharmaceuticals, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T22:44:22.507Z"
locales:
  - [en](https://longbridge.com/en/quote/MIRM.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MIRM.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MIRM.US.md)
---

# Mirum Pharmaceuticals, Inc. (MIRM.US)

## Company Overview

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.mirumpharma.com](https://www.mirumpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:14.000Z

**Overall: C (0.51)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 77 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 50.19% |  |
| Net Profit YoY | -932.90% |  |
| P/B Ratio | 24.01 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5823097366.23 |  |
| Revenue | 569609000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -335.82% | E |
| Profit Margin | -140.24% | E |
| Gross Margin | 81.98% | A |
| Revenue YoY | 50.19% | A |
| Net Profit YoY | -932.90% | E |
| Total Assets YoY | 29.07% | A |
| Net Assets YoY | 3.96% | C |
| Cash Flow Margin | 21.40% | D |
| OCF YoY | 50.19% | A |
| Turnover | 0.72 | B |
| Gearing Ratio | 72.78% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Mirum Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "50.19%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-932.90%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "24.01",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "5823097366.23",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "569609000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-335.82%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-140.24%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "81.98%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "50.19%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-932.90%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "29.07%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "3.96%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "21.40%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "50.19%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.72",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "72.78%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -7.29 | 413/386 | - | - | - |
| PB | 24.01 | 425/386 | 18.06 | 14.32 | 11.20 |
| PS (TTM) | 10.22 | 165/386 | 10.80 | 8.58 | 6.89 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **11**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 73% |
| Overweight | 3 | 27% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 95.65 |
| Highest Target | 150.00 |
| Lowest Target | 112.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/MIRM.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/MIRM.US/norm.md)
- [Related News](https://longbridge.com/en/quote/MIRM.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/MIRM.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**